A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm. The post New state-of-the-art test identifies ...

By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...

News, features, and commentary about cancer-related issues ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...